GSA Capital Partners
ATYR icon

GSA Capital Partners’s aTyr Pharma ATYR Stock Holding History

GSA Capital Partners’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.06M Buy
86,372
+44,257
+105% +$1.16M 0.13% 152
2026
Q1 		$1.31M Sell
42,115
-23,651
-36% -$799K 0.08% 348
2025
Q4 		$2.06M Buy
65,766
+48,098
+272% +$1.58M 0.18% 77
2025
Q3 		$510K Buy
17,668
+5,261
+42% +$954K 0.04% 839
2025
Q2 		$2.52M Buy
12,407
+4,099
+49% +$645K 0.18% 72
2025
Q1 		$1M Buy
8,308
+1,447
+21% +$211K 0.09% 340
2024
Q4 		$993K Sell
6,861
-304
-4% -$36.8K 0.07% 417
2024
Q3 		$504K Sell
7,165
-897
-11% -$65.3K 0.04% 902
2024
Q2 		$503K Buy
8,062
+2,458
+44% +$171K 0.04% 962
2024
Q1 		$437K Buy
5,604
+2,875
+105% +$201K 0.03% 970
2023
Q4 		$154K Buy
2,729
+2,040
+296% +$105K 0.01% 1366
2023
Q3 		$44K Buy
+689
New +$51K ﹤0.01% 1423
2022
Q1 		– Sell
-1,470
Closed -$439K – 1914
2021
Q4 		$439K Buy
+1,470
New +$491K 0.06% 686
2016
Q3 		– Sell
-65
Closed -$101K – 2008
2016
Q2 		$101K Buy
+65
New +$121K 0.01% 1667

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $132M AUM 92.09% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GSA Capital Partners's ATYR Position: Q2 2026 in Review

GSA Capital Partners increased its aTyr Pharma (ATYR) stake by 105% in Q2 2026, buying an estimated $1.16M and bringing the position to 86,372 shares worth $2.06M. The position accounts for 0.13% of the portfolio, ranked #152.

GSA Capital Partners first reported a position in ATYR in Q2 2016 and has held it in 14 quarters since. The position peaked at $2.52M in Q2 2025. 87 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • GSA Capital Partners held 86,372 shares of aTyr Pharma worth $2.06M as of Q2 2026.
  • GSA Capital Partners bought 44,257 aTyr Pharma shares in Q2 2026, an estimated $1.16M.
  • aTyr Pharma made up 0.13% of GSA Capital Partners's portfolio in Q2 2026, its #152 holding.
  • GSA Capital Partners first reported a position in aTyr Pharma in Q2 2016 and has held it in 14 quarters since.
  • GSA Capital Partners's aTyr Pharma position peaked at $2.52M in Q2 2025.
  • 87 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.